Last updated on November 2017

A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced EjectionFraction (VICTORIA)


Brief description of study

A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced EjectionFraction (VICTORIA)

Detailed Study Description

Male and female subjects aged 18 years or older, with chronic HF (NYHA class II-IV), reduced ejection fraction (< 45%), elevated natriuretic peptides, and previous HFdecompensation (defined as HF hospitalization or use of IV diuretics for HF [without hospitalization]) will be enrolled in this trial.

Clinical Study Identifier: TX82104

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Research Center

Columbus Regional Research Institute
Columbus, GA USA
  Connect »